Bronchogen is a short synthetic peptide from the Russian Khavinson “bioregulator” family, marketed as a bronchial and respiratory-system regulator. Like related peptides in this family, it is sold today mostly as an oral capsule through longevity and biohacking resellers rather than as a registered medicine. It is frequently confused with, or marketed alongside, a related product called Chonluten, and vendor pages do not consistently distinguish the two.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” tetrapeptide, marketed as a bronchial/respiratory-system regulator |
| Primary research interest | Bronchial and lung tissue support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — frequently confused with, or marketed alongside, a related product called Chonluten, with vendor pages not consistently distinguishing the two |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold mostly as an oral capsule through longevity/biohacking resellers |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Bronchogen |
| Alternative names | Frequently confused with or marketed alongside Chonluten |
| Peptide sequence | Most commonly described by vendors as Ala-Glu-Asp-Leu (“AEDL”); not independently confirmed against a primary chemical database |
| Amino-acid length | 4 (tetrapeptide, per vendor description) |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator” peptide line, developed beginning in the 1970s-1980s |
| Primary biological target | Not established — proposed bronchial/lung tissue activity, not confirmed via primary literature |
| Developer or originator | Vladimir Khavinson’s group, for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Bronchogen is part of the same short-peptide “bioregulator” concept developed by Vladimir Khavinson’s group beginning in the 1970s-1980s, in which very short peptides (three to four amino acids) are proposed to act preferentially on the organ system they were modeled after — in this case the bronchi and lung tissue.
Vendor listings most commonly describe Bronchogen as a tetrapeptide, with the sequence Ala-Glu-Asp-Leu (AEDL) appearing on a number of reseller sites. However, this same AEDL sequence is also frequently attributed to Chonluten by other sellers, and some sites reverse the attribution entirely. PeptideBlog.net could not locate an authoritative, independent source that consistently and reliably separates the two by sequence — this is a genuine, unresolved conflict in the publicly available material rather than a simple oversight, and it should be treated as such.
Neither Bronchogen nor its sequence identity have been verified against a primary chemical database (no confirmed CAS number, PubChem CID, or UNII record was located). It is not an approved pharmaceutical in the United States and does not appear to hold clear independent pharmaceutical registration in Russia either.
How does it work?
Plain-English explanation
The proposed idea is that Bronchogen supports normal function and turnover of bronchial and lung tissue cells, similar in concept to how other peptides in this family are proposed to act on their target organs. This is a hypothesis from the developers rather than a demonstrated human effect.
Technical explanation
As with other Khavinson-family peptides, the proposed mechanism involves short-peptide interaction with chromatin or gene-regulatory elements affecting cell differentiation in respiratory epithelium. This has not been independently confirmed outside the developing research group, and no pharmacokinetic data for oral administration was identified.
Potential benefits and research applications
Respiratory tissue support
What is being investigated: whether Bronchogen supports normal bronchial/lung cell function, including in the context of chronic bronchitis or age-related decline, per developer materials. How the effect might occur: proposed gene-regulatory action in respiratory epithelium. Evidence: limited animal/laboratory work from the originating Russian research network; independent replication was not identified. Strength: weak (Tier 3/4 at best). Limitation: no controlled human trial data was found, and the sequence-identity conflict with Chonluten further muddies what exactly has been studied under this name.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified.
Amounts studied in animal research
Not consistently reported. General Khavinson-group animal aging studies are referenced by resellers, but specific extractable dose figures for Bronchogen were not identified.
Practitioner and community-reported protocols
Vendor pages commonly list 10-20 mg oral capsules, generally one capsule daily for roughly 10-20 days, sometimes marketed toward smokers, seasonal respiratory support, or general lung-aging concerns. This is vendor/community-reported (Tier 6) information, not a clinical protocol, and figures are essentially identical to those given for Chonluten on many sites — which reinforces that the two names are not reliably distinguished by dose either.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General respiratory/lung support (community use) | Oral capsule | 10-20 mg per capsule | Once daily | Roughly 10-20 day cycles |
Vendor sources commonly describe 10-20 mg oral capsules taken once daily for about 10-20 days, often marketed for general lung/respiratory support.
These figures are widely repeated online and are essentially identical to those given for Chonluten by many of the same sellers; the original clinical source, if any, could not be verified.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No systematic human safety data was identified. General risks applicable to unregulated peptide supplements apply: unverified purity and identity, uncertain oral bioavailability, no long-term safety monitoring, and supply-chain risks such as mislabeling or incorrect concentration. The unresolved naming/sequence overlap with Chonluten adds an additional identity-verification concern for anyone trying to compare products.
Regulatory and developmental status
Bronchogen is not FDA approved and has no FDA-recognized indication. No clear independent pharmaceutical registration was identified in Russia either; it circulates as a supplement product. Status verified as of the review date below.
Frequently asked questions
What is Bronchogen?
Bronchogen is a short Khavinson-family synthetic peptide marketed as a bronchial/respiratory-system bioregulator, sold mainly as an oral supplement.
How is Bronchogen different from Chonluten?
Both are marketed as lung/bronchial bioregulators from the same research family, and vendor sources are inconsistent about which sequence and which specific respiratory role belongs to which name. This page treats that as an unresolved conflict rather than picking one version silently.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified.
What dosage commonly circulates online?
Vendors commonly describe 10-20 mg oral capsules taken once daily for roughly 10-20 days, but this is vendor/community-reported, not a clinical dose.
Is Bronchogen approved by any regulator?
No. It has no identified FDA or other formal regulatory approval.
Bottom line
Bronchogen is a thinly documented Khavinson-family peptide whose identity is genuinely tangled up with the related product Chonluten across commercial sources. Whatever mechanistic or animal work underlies the concept comes almost entirely from the originating research group, with no independent human clinical evidence and no verified chemical identifiers. Reported oral dosing is vendor/community information only.